

Statement regarding use of non-GAAP financial measures

In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached schedules.

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets: Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights.
- Acquisition – integration related costs: Costs related to closing and integration of acquired companies
- Non-recurring legal expenses: One-time non-recurring legal settlements
- Tax impact related to equity compensation: Changes in effective tax rate based upon ASU 2016-09
- Potential future consideration related to acquisitions: Non-cash expenses related to valuation adjustments of earn-out and milestone payments tied to recent acquisitions
- Impairment of Raindance Investment: One-time impairment charge associated with Myriad's investment in Raindance Technologies
- One-time debt restructuring costs: Charges related to the restructuring of the company's debt from a one-year term loan to a revolving credit facility
- One-time non-deductible costs: One-time non-deductible tax items
- Tax reform impact on deferred taxes: One-time non-cash charges associated with change in value of our deferred tax assets due to tax reform
- Elevate 2020 costs: Expenses tied to Elevate 2020 program
- Non-recurring bad debt reserve: Changes in bad debt reserve tied to prior period adjustments

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully

understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

**Reconciliation of GAAP to Non-GAAP Financial Measures
for the Three and Twelve Months ended June 30, 2018**

(Unaudited data in millions, except per share amount)

	Three Months Ended		Twelve Months Ended	
	Jun 30, 2018	Jun 30, 2017 (Restated)	Jun 30, 2018	Jun 30, 2017 (Restated)
<i>Revenue</i>	\$ 200.9	\$ 199.6	\$ 772.6	\$ 769.9
GAAP Cost of molecular diagnostic testing	\$ 38.0	\$ 35.6	\$ 148.7	\$ 145.2
GAAP Cost of pharmaceutical and clinical services	7.7	6.9	28.5	26.0
Acquisition - Integration related costs	-	-	-	(0.1)
Elevate 2020 costs	(2.8)	-	(3.0)	-
Non-GAAP COGS	\$ 42.9	\$ 42.5	\$ 174.2	\$ 171.1
Non-GAAP Gross Margin	79%	79%	77%	78%
GAAP Research and Development	\$ 17.7	\$ 18.8	\$ 70.8	\$ 74.4
Acquisition - Integration related costs	-	(0.1)	(0.1)	(0.2)
Acquisition - amortization of intangible assets	(0.1)	(0.1)	(0.3)	(0.3)
Elevate 2020 costs	(0.7)	-	(1.8)	-
Non-GAAP R&D	\$ 16.9	\$ 18.6	\$ 68.6	\$ 73.9
GAAP Contingent Consideration	\$ 0.2	\$ (2.7)	\$ (61.2)	\$ (0.8)
Potential future consideration related to acquisitions	(0.2)	2.7	61.2	0.8
Non-GAAP Contingent Consideration	\$ -	\$ -	\$ -	\$ -
GAAP Selling, General and Administrative	\$ 121.4	\$ 122.1	\$ 467.1	\$ 476.4
Acquisition - Integration related costs	(0.6)	(0.7)	(0.9)	(13.6)
Acquisition - amortization of intangible assets	(9.1)	(9.1)	(36.6)	(32.7)
Non-recurring bad debt reserve	(2.5)	-	(2.5)	-
Non-recurring legal expenses	(0.5)	(0.6)	(0.5)	(0.6)
Elevate 2020 costs	(2.5)	(0.3)	(7.2)	(0.3)
Non-GAAP SG&A	\$ 106.2	\$ 111.4	\$ 419.4	\$ 429.2
GAAP Operating Income	\$ 15.9	\$ 18.9	\$ 118.7	\$ 48.7
Acquisition - Integration related costs	0.6	0.8	1.0	13.9
Acquisition - amortization of intangible assets	9.2	9.2	36.9	33.0
Non-recurring bad debt reserve	2.5	-	2.5	-
Non-recurring legal expenses	0.5	0.6	0.5	0.6
Elevate 2020 costs	6.0	0.3	12.0	0.3
Potential future consideration related to acquisitions	0.2	(2.7)	(61.2)	(0.8)
Non-GAAP Operating Income	\$ 34.9	\$ 27.1	\$ 110.4	\$ 95.7
Non-GAAP Operating Margin	17%	14%	14%	12%
GAAP Net Income Attributable to Myriad Genetics, Inc. Stockholders	\$ 13.1	\$ 12.3	\$ 131.0	\$ 20.5
Acquisition - Integration related costs	0.6	0.8	1.0	13.9
Acquisition - amortization of intangible assets	9.2	9.2	36.9	33.0
Non-recurring bad debt reserve	2.5	-	2.5	-
Non-recurring legal expenses	0.5	0.6	0.5	0.6
Elevate 2020 costs	6.0	0.3	12.0	0.3
Potential future consideration related to acquisitions	0.2	(2.7)	(61.2)	(0.8)
Tax impact related to equity compensation	(0.1)	0.1	(0.4)	3.0
One-time debt restructuring costs	-	-	-	1.3
One-time non-deductible costs	-	-	-	2.7
Tax reform effect	(1.8)	-	(32.0)	-
Impairment of Raindance Investment	-	-	-	2.4
Tax effect associated with non-GAAP adjustments	(2.6)	(0.4)	(4.2)	(5.8)
Non-GAAP Net Income	\$ 27.6	\$ 20.2	\$ 86.1	\$ 71.1
GAAP Diluted EPS	\$ 0.18	\$ 0.18	\$ 1.82	\$ 0.30
Non-GAAP Diluted EPS	\$ 0.38	\$ 0.29	\$ 1.20	\$ 1.03
<i>Diluted shares outstanding</i>	72.9	68.9	72.0	68.8

Free Cash Flow Reconciliation
(Unaudited data in millions)

	Three Months Ended		Twelve Months Ended	
	Jun 30, 2018	Jun 30, 2017 (Restated)	Jun 30, 2018	Jun 30, 2017 (Restated)
GAAP cash flow from operations	\$ 47.9	\$ 36.6	\$ 115.9	\$ 106.2
Capital expenditures	(1.8)	(0.7)	(8.4)	(6.1)
Free cash flow	\$ 46.1	\$ 35.9	\$ 107.5	\$ 100.1
Elevate 2020 costs	3.7	0.3	9.7	0.3
Acquisition - Integration related costs	0.6	0.8	-	8.7
Cash paid for contingent consideration in operating cash flows	1.9	-	22.7	-
Cash paid at closing to Assurex vendors	-	-	-	6.8
Accrual for legal expenses	-	0.6	-	0.6
Tax effect associated with non-GAAP adjustments	(1.7)	(0.6)	(9.1)	(5.7)
Non-GAAP Free cash flow	\$ 50.6	\$ 37.0	\$ 130.8	\$ 110.8

Reconciliation of GAAP to Non-GAAP for Fiscal Year 2019

The Company's future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from guidance set forth below. Some of the factors that could affect the Company's financial results are stated in the safe harbor statement of this press release. More information on potential factors that could affect the Company's financial results are included under the heading "Risk Factors" contained in Item 1A in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

	<u>Fiscal Year 2019</u>
Diluted net income per share	
GAAP diluted net income per share	\$0.40- \$0.45
Stock Based Compensation Expense	0.30
Acquisition - amortization of intangible assets	0.80
One-time expenses	0.20
Non-GAAP diluted net income per share	<u><u>\$1.70 - \$1.75</u></u>
	<u>Fiscal First-Quarter 2019</u>
Diluted net income per share	
GAAP diluted net income per share	(\$0.08) - (\$0.06)
Stock Based Compensation Expense	0.08
Acquisition - amortization of intangible assets	0.18
One-time expenses	0.10
Non-GAAP diluted net income per share	<u><u>\$0.28 - \$0.30</u></u>